An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorderGroenman, A. P., Schweren, L. J. S., Dietrich, A. & Hoekstra, P. J., Apr-2017, In : Expert Opinion on Drug Safety. 16, 4, p. 455-464 10 p.
Research output: Contribution to journal › Review article › Academic › peer-review
Introduction: Methylphenidate is the first-line pharmacological treatment of attention-deficit/hyperactivity disorder (ADHD). Although methylphenidate has a well-established evidence base for treating ADHD, its long-term benefits are unclear.Areas covered: Physical adverse effects, psychiatric adverse events and brain developmentExpert opinion: Some physical adverse events have been described (e.g. sleep disturbances, growth reduction, loss of appetite), although most are of transient nature. Psychiatric adverse events seem more related to the diagnosis ADHD itself, and not stimulant treatment. Concluding, short-to-mid-term use (i.e., up to 2years) stimulants are relatively safe, but much less is known about longer-term efficacy and safety of these drugs.
|Number of pages||10|
|Journal||Expert Opinion on Drug Safety|
|Publication status||Published - Apr-2017|
- ADHD, stimulant treatment, methylphenidate, safety, DEFICIT-HYPERACTIVITY DISORDER, FUNCTIONAL MAGNETIC-RESONANCE, OF-THE-LITERATURE, SERIOUS CARDIOVASCULAR EVENTS, COMORBID TIC DISORDER, LA-TOURETTES SYNDROME, STIMULANT TREATMENT, SUBSTANCE USE, METHYLPHENIDATE TREATMENT, MULTIMODAL TREATMENT